BMY
BristolMyers Squibb Company
Stock NYSE – Stock Market Prices, News & Analysis
Bristol-Myers Squibb is an American pharmaceutical company specializing in the discovery, development, and commercialization of drugs for various therapeutic areas.
BristolMyers Squibb Company
BMY
Bristol-Myers Squibb is an American pharmaceutical company specializing in the discovery, development, and commercialization of drugs for various therapeutic areas.
Price history of BristolMyers Squibb Company
Price history of BristolMyers Squibb Company
Performance & Momentum
Bristol-Myers Bolsters Oncology Pipeline with AI, Partnerships
Bristol-Myers Squibb (BMY) recently announced strategic collaborations, including a partnership with Microsoft to leverage artificial intelligence for early lung cancer detection and an alliance with Janux Therapeutics to develop treatments targeting solid tumors. These efforts aim to expand its digital health capabilities and strengthen its oncology position, a key sector for the company. Additionally, Citi raised its price target to $60 while maintaining a neutral rating, reflecting a positive sector outlook and optimistic forecasts for 2026.
Strategic Analysis
BristolMyers Squibb Company • 2026
Bristol-Myers Squibb positions itself as a major player in innovative pharmaceuticals, with a model focused on advanced research in oncology and neurodegenerative diseases. Its strategy prioritizes the development of cutting-edge therapies, such as CAR-T, and the exploration of new indications, strengthening its niche in high-value specialty treatments.
Strengths
- Leadership in oncology innovation with the approval of Breyanzi, the first CAR T therapy for a rare lymphoma.
- Strong pipeline with ongoing efforts in Alzheimer’s research, demonstrating targeted therapeutic diversification.
- Ability to quickly mobilize resources for ambitious clinical trials, supporting medium-term growth.
Weaknesses
- Volatile stock performance in the medium term, reflecting challenges in generating stable growth.
- Reliance on regulatory successes for innovative products still in development.
Momentum
The momentum reflects a cautious yet promising dynamic, fueled by recent positive announcements such as the approval of Breyanzi and progress in Alzheimer’s trials. This trend, supported by scientific advancements, suggests enhanced valuation potential in the medium term, contrasting with a more mixed historical performance.
Similar stocks to BristolMyers Squibb Company
Recent News
BristolMyers Squibb Company
UBS Raises Bristol-Myers Squibb Price Target to $65
2 months agoBristol-Myers Squibb (Bristol-Myers Squibb Company) is benefiting from renewed optimism in the biotech and pharma sectors. UBS upgraded its rating to "Buy," increasing its price target from $46 to $65, highlighting a positive sector turnaround. Additionally, Leerink maintains an "Outperform" rating with a $60 target, relying on multiple clinical results expected in 2026, which strengthens the stock’s growth outlook. Despite a recent slight pullback, strong institutional investor interest indicates heightened sensitivity to the stock price but also underscores confidence in the company’s long-term potential.
FDA Approves Breyanzi, First CAR T for Rare Lymphoma
3 months agoThe FDA's recent approval of Breyanzi, the first CAR T therapy for marginal zone lymphoma, represents a major breakthrough for Bristol-Myers Squibb. This decision is accompanied by a price target upgrade from Goldman Sachs, boosting optimism about the company's long-term growth potential. Despite a slight 0.7% decline, the market remains generally confident in the positive impact of this therapeutic innovation.
Bristol Myers Expands Alzheimer Trial, Shares Rise
4 months agoOn December 3, 2025, Bristol Myers announced an expansion in patient recruitment for its Alzheimer’s clinical trial, driving a notable 3.7% rise in its stock before market open. This increase reflects strong investor optimism about potential treatment advances, despite a current mild daily dip of -1.89%, which remains moderate compared to the recent positive momentum.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
